Horizon Therapeutics plc: Topline Data for Dazodalibep (HZN-4920) Meets Primary Endpoint in Rheumatoid Arthritis

Detailed results to be presented at upcoming medical congress Horizon Therapeutics plc (Nasdaq: HZNP) today announced that its Phase 2, randomized, double-blinded, placebo-controlled trial of dazodalibep

Related Keywords

United States ,Ireland ,Putte ,Mecklenburg Vorpommern ,Germany ,Theresa Podrebarac ,Tina Ventura ,Geoff Curtis ,Ray Gordon ,Exchange Commission ,Instagram ,Linkedin ,Twitter ,Facebook ,Nasdaq ,Corporate Affairs ,United States Securities ,Vice President ,Chief Investor Relations Officer ,Corporate Affairs Chief Communications Officer ,Horizon ,Herapeutics ,Topline ,Data ,Azodalibep ,920 ,Meets ,Primary ,Ndpoint ,Rheumatoid ,Arthritis ,